Recent Progress in Glucose-Responsive Insulin
Diabetes · 01.09.2024 · 73 (9) · 1377-1388
DOI: 10.2337/dbi23-0028 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, online erschienen am 10.06.2024. Verfasst von Yun Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Insulin, Hypoglycemic Agents, Blood Glucose. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: the Starry Night Science Fund at Shanghai Institute for Advanced Study of Zhejiang University, Breakthrough T1D, Chinese Polar Environment Comprehensive Investigation and Assessment Programmes.
Abstract (Originalsprache)
Insulin replacement therapy is indispensable in the treatment of type 1 and advanced type 2 diabetes. However, insulin’s clinical application is challenging due to its narrow therapeutic index. To mitigate acute and chronic risks of glucose excursions, glucose-responsive insulin (GRI) has long been pursued for clinical application. By integrating GRI with glucose-sensitive elements, GRI is capable of releasing or activating insulin in response to plasma or interstitial glucose levels without external monitoring, thereby improving glycemic control and reducing hypoglycemic risk. In this Perspective, we first introduce the history of GRI development and then review major glucose-responsive components that can be leveraged to control insulin delivery. Subsequently, we highlight the recent advances in GRI delivery carriers and insulin analogs. Finally, we provide a look to the future and the challenges of clinical application of GRI. Article Highlights
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
- Jinhua Institute of Zhejiang University, Jinhua, China.
- Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
- Department of Chemistry, College of Sciences, Northeastern University, Shenyang, China.
- Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China.
ORCID-Profile: John B Buse, Zhen Gu
Förderung
- the Starry Night Science Fund at Shanghai Institute for Advanced Study of Zhejiang University
- Breakthrough T1D
- Chinese Polar Environment Comprehensive Investigation and Assessment Programmes
- National Natural Science Foundation of China
- Kunpeng program from Zhejiang Province
- the Startup Packages of Zhejiang University
- Fundamental Research Funds for the Central Universities
- JDRF
Zitieren
APA
Liu, Y., Wang, S., Wang, Z., Yu, J., Wang, J., Buse, J. B., & Gu, Z. (2024). Recent Progress in Glucose-Responsive Insulin. Diabetes, 73(9), 1377-1388. https://doi.org/10.2337/dbi23-0028
Vancouver
Liu Y, Wang S, Wang Z, Yu J, Wang J, Buse JB, et al. Recent Progress in Glucose-Responsive Insulin. Diabetes. 2024;73(9):1377-1388. doi:10.2337/dbi23-0028
BibTeX
@article{Liu2024,
author = {Liu, Yun and Wang, Shiqi and Wang, Zejun and Yu, Jicheng and Wang, Jinqiang and Buse, John B and Gu, Zhen},
title = {Recent Progress in Glucose-Responsive Insulin},
journal = {Diabetes},
year = {2024},
volume = {73},
number = {9},
pages = {1377--1388},
doi = {10.2337/dbi23-0028}
}
EUVIMED